Prodrug activation at tumor site

Prodrug activation at tumor site describes a drug design and delivery strategy where a pharmacologically inactive prodrug is converted to its active form specifically within tumor tissue. Activation mechanisms may exploit unique tumor-associated enzymes (like PSA, PSMA, β-galactosidase), microenvironmental features (pH, hypoxia, glutathione), externally applied physical energies (radiotherapy), or engineered bacterial vectors, all aiming to maximize anti-tumor efficacy while minimizing adverse effects on normal tissue. This is not a molecular entity but a therapeutic concept used to engineer site-specific cancer therapies such as ADEPT, GDEPT, radiotherapy-activated prodrugs, and microenvironment-responsive nanoparticles.

Other names

Tumor-localized prodrug activationSite-specific prodrug activationTumor-selective prodrug activation

Enzyme-mediated prodrug activation (e.g., by PSA, PSMA, β-galactosidase); Microenvironment-responsive activation (e.g., acid, hypoxia, redox conditions); Radiotherapy/catalytic activation (e.g., water radiolysis producing hydrated electrons activating prodrugs); Antibody-directed enzyme prodrug therapy (ADEPT); Gene-directed enzyme prodrug therapy (GDEPT); Bacterial vector-mediated chemical linker cleavage